Clinical Trial Detail

NCT ID NCT01148849
Title Safety Study of MGAH22 in HER2-positive Carcinomas
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors MacroGenics
Indications

breast cancer

carcinoma

stomach cancer

Therapies

Margetuximab

Age Groups: adult senior

Additional content available in CKB BOOST